$ 97.99See all
VEZUGEN is a complex peptide, comprising amino acids that contribute to the normalization of functional state of vessels, in particular, lysine, glutamic and aspartic acid. They regulate the metabolism in the cells of the vascular wall, improve the condition of the vessel walls and normalize lipid metabolism.
Diseases of the cardiovascular system significantly reduce the quality and duration of life lead to disability and even death. Their cause is changes in the vascular wall, eating disorders tissues and as a result, blood flow obstruction. Vezugen was designed as a bioregulator for vessels. He successfully corrects the pathological changes that occur in the blood vessels in most diseases.
Vezugen recommended for:
Vezugen: clinical trials
Studies have confirmed the effectiveness of the drug in the complex vascular disease prevention in the elderly, as well as in the treatment and prophylaxis of patients with cerebral arteriosclerosis, heart and vessels of the lower extremities. Vezugen also shown for violations of microcirculation in organs and tissues, and psycho-emotional stress.
Use of the drug in patients with coronary heart disease reduced the number of angina attacks, reduce the appearance of cardiac arrhythmias. In patients with atherosclerosis of the arteries Vezugen improves overall health, normalizes sleep. Hypertension drug in combination with antihypertensive agents can achieve long-term remission.
In a clinical study VEZUGEN attended by 87 patients with atherosclerotic vessels, 53 of which were the main group (33 men, 20 women) - to them in addition to the conventional means of appointed Vezugen orally 1-2 capsules with meals 1-2 times a day for 20 - 30 days depending on the severity of the pathological process. 34 patients (18 men, 16 women), entered into the control group was administered only conventional means. The age of patients in both groups ranged from 50 to 82 years.
Patients in both groups were observed different clinical manifestations of atherosclerosis, depending on the vascular lesions of different caliber: hypertension, coronary heart disease with coronary artery disease, cerebrovascular disorders with memory impairment, concentration, attention, affective lability in patients with cerebral atherosclerosis. All patients had progressive dynamics of the disease. All patients had previously received symptomatic and pathogenetic therapy for specific clinical manifestations of vascular disease. We evaluated the dynamics of patients' complaints, clinical blood and urine tests, blood biochemistry. In order to study the homeostasis of blood coagulation were determined and used to harness the Hess trial.
It was established that VEZUGEN use in patients with atherosclerosis of the arteries contribute to the improvement of general well-being, sleep normalization, especially in patients with cerebrovascular disorders. Patients with coronary heart disease have noted a decrease in the manifestations of abnormal heart rhythm, slowing strokes. Patients with hypertension associated normalization of blood pressure using VEZUGEN in combination with antihypertensive agents as able to achieve long-term remission between hypertensive crises at a lower dose of conventional antihypertensive drugs.
As can be seen from the table, use VEZUGEN contributed to a significant decrease in total cholesterol levels in the blood.
Also, there was a tendency to reduce the content of very low density lipoproteins, which are the most atherogenic.
Thus, the results of the study demonstrate therapeutic efficacy VEZUGEN and feasibility of its application in the integrated prevention and treatment of atherosclerosis.
Adults take 1-2 capsules 1-2 times a day with meals. Duration of 10-30 days. It is advisable to repeat the course in 4-6 months.
Important notice - the outer box design may vary before prior notice!